KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Rigel Pharmaceuticals (RIGL) Equity Ratio: 2009-2025

Historic Equity Ratio for Rigel Pharmaceuticals (RIGL) over the last 16 years, with Sep 2025 value amounting to 0.48.

  • Rigel Pharmaceuticals' Equity Ratio rose 561.92% to 0.48 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.48, marking a year-over-year increase of 561.92%. This contributed to the annual value of 0.02 for FY2024, which is 108.21% up from last year.
  • Latest data reveals that Rigel Pharmaceuticals reported Equity Ratio of 0.48 as of Q3 2025, which was up 22.35% from 0.40 recorded in Q2 2025.
  • Over the past 5 years, Rigel Pharmaceuticals' Equity Ratio peaked at 0.48 during Q3 2025, and registered a low of -0.28 during Q3 2023.
  • Over the past 3 years, Rigel Pharmaceuticals' median Equity Ratio value was -0.20 (recorded in 2023), while the average stood at -0.05.
  • As far as peak fluctuations go, Rigel Pharmaceuticals' Equity Ratio plummeted by 735.86% in 2023, and later skyrocketed by 561.92% in 2025.
  • Over the past 5 years, Rigel Pharmaceuticals' Equity Ratio (Quarterly) stood at 0.18 in 2021, then slumped by 155.86% to -0.10 in 2022, then tumbled by 140.97% to -0.24 in 2023, then spiked by 108.21% to 0.02 in 2024, then surged by 561.92% to 0.48 in 2025.
  • Its Equity Ratio stands at 0.48 for Q3 2025, versus 0.40 for Q2 2025 and 0.11 for Q1 2025.